MMP-2 regulates human platelet activation by interacting with integrin α IIb β 3

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 3, 2008, Pages 517-523

  Choi, W S ^a   Jeon, O H ^a   Kim, H H ^a   Kim, D S ^a  

^a Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B BETA3 INTEGRIN; FIBRINOGEN; GELATINASE A; HEMOPEXIN; INTEGRIN; MATRIX METALLOPROTEINASE; PADGEM PROTEIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME BINDING; ENZYME RELEASE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REGULATORY MECHANISM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; WESTERN BLOTTING;

AMINO ACID MOTIFS; BLOOD PLATELETS; CATALYTIC DOMAIN; CELL MEMBRANE; COLLAGEN; FIBRINOGEN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEMOPEXIN; HUMANS; MATRIX METALLOPROTEINASE 2; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 39549089084     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02871.x     Document Type: Article

References (33)

1. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
2. Jurasz P, Chung AW, Radomski A, Radomski MW. Nonremodeling properties of matrix metalloproteinases: The platelet connection. Circ Res 2002; 90: 1041-3.
3. Santos-Martinez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res 2007; doi: 10.1016/j.thromres.2007.06.002.
4. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386: 616-9.
5. Sawicki G, Sanders EJ, Salas E, Wozniak M, Rodrigo J, Radomski MW. Localization and translocation of MMP-2 during aggregation of human platelets. Thromb Haemost 1998; 80: 836-9.
6. Kazes I, Elalamy I, Sraer JD, Hatmi M, Nguyen G. Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: Involvement in MMP2 activation and platelet aggregation. Blood 2000; 96: 3064-9.
7. Murphy G, Nguyen Q, Cockett MI, Atkinson SJ, Allan JA, Knight CG, Willenbrock F, Docherty AJ. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem 1994; 269: 6632-6.
8. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92: 391-400.
9. Falcinelli E, Guglielmini G, Torti M, Gresele P. Intraplatelet signaling mechanisms of the priming effect of matrix metalloproteinase-2 on platelet aggregation. J Thromb Haemost 2005; 3: 2526-35.
10. Flaumenhaft R, Dilks JR, Rozenvayn N, Monahan-Earley RA, Feng D, Dvorak AM. The actin cytoskeleton differentially regulates platelet alpha-granule and dense-granule secretion. Blood 2005; 105: 3879-87.
11. Ni H, Freedman J. Platelets in hemostasis and thrombosis: Role of integrins and their ligands. Transfus Apher Sci 2003; 28: 257-64.
12. Michelson AD. Flow cytometry: A clinical test of platelet function. Blood 1996; 87: 4925-36.
13. McCawley LJ, Matrisian LM. Matrix metalloproteinases: They're not just for matrix anymore! Curr Opin Cell Biol 2001; 13: 534-40.
14. Andrews RK, Karunakaran D, Gardiner EE, Berndt MC. Platelet receptor proteolysis: A mechanism for downregulating platelet reactivity. Arterioscler Thromb Vasc Biol 2007; 27: 1511-20.
15. Martinez A, Salas E, Radomski A, Radomski MW. Matrix metalloproteinase-2 in platelet adhesion to fibrinogen: Interactions with nitric oxide. Med Sci Monit 2001; 7: 646-51.
16. Puyraimond A, Fridman R, Lemesle M, Arbeille B, Menashi S. MMP-2 colocalizes with caveolae on the surface of endothelial cells. Exp Cell Res 2001; 262: 28-36.
17. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004; 6: 507-14.
18. Yang Z, Strickland DK, Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 2001; 276: 8403-8.
19. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85: 683-93.
20. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 2001; 98: 119-24.
21. Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW, Strongin AY. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 2001; 263: 209-23.
22. Pfeifer A, Kessler T, Silletti S, Cheresh DA, Verma IM. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci USA 2000; 97: 12227-32.
23. Kasirer-Friede A, Kahn ML, Shattil SJ. Platelet integrins and immunoreceptors. Immunol Rev 2007; 218: 247-64.
24. Hu DD, White CA, Panzer-Knodle S, Page JD, Nicholson N, Smith JW. A new model of dual interacting ligand binding sites on integrin alphaIIbbeta3. J Biol Chem 1999; 274: 4633-9.
25. Litvinov RI, Bennett JS, Weisel JW, Shuman H. Multi-step fibrinogen binding to the integrin (alpha)IIb(beta)3 detected using force spectroscopy. Biophys J 2005; 89: 2824-34.
26. Stefanidakis M, Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: Role of the complexes in leukocyte migration and cancer progression. Blood 2006; 108: 1441-50.
27. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996; 93: 7069-74.
28. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 1997; 272: 31730-7.
29. Schneider DJ, Sobel BE. Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circulation 2007; 116: 305-15.
30. Dogne JM, Hanson J, Supuran C, Pratico D. Coxibs and cardiovascular side-effects: From light to shadow. Curr Pharm Des 2006; 12: 971-5.
31. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007; 115: 2196-207.
32. Aster RH, Curtis BR, Bougie DW. Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors. Semin Thromb Hemost 2004; 30: 569-77.
33. Davoren A, Aster RH. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol 2006; 81: 36-44.